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The development of extensive and severe non-melanoma skin cancer is an extremely common complication of
organ transplantation and is assumed to be caused by long-term treatment with anti-rejection drugs (ARD). Despite
this ﬂorid clinical problem, ARD treatments have been reported to affect experimental murine skin carcinogenesis
only weakly. We report here that treatment of cesium-137-irradiated Ptch1þ / mice with immunosuppressive
doses of cyclosporine A plus prednisolone for 4-1/2 mo increased basal cell carcinoma burden by 2.5-fold. Thus,
these mice provide a good model for study of the effects of long-term administration of ARD on at least one type of
non-melanoma skin cancer.
Key words: basal cell carcinoma/cyclosporine A/hedgehog/organ transplantation/patched
J Invest Dermatol 124:263 –267, 2005
Among organ transplant recipients (OTR) of European de-
scent who receive long-term anti-rejection drug (ARD) med-
ication, the incidence of non-melanoma skin cancer (NMSC)
is 19%–31% by 5 y and 33%–72% by 10–20 y after trans-
plantation, an increase of 39–100-fold over that expected in
matched non-OTR (Penn, 1994, 1998; Jensen et al, 1999;
Kyllonen et al, 2000; Lindelof et al, 2000; Naldi et al, 2000;
Thakur et al, 2001; Euvrard et al, 2003). Quite often, these
NMSC have aggressive biology and uncommon morphol-
ogy (Green et al, 1999). The increased NMSC incidence is
accompanied by a shift of the usual basal cell carcinoma
(BCC):squamous cell carcinoma (SCC) ratio from approx-
imately 3:1 to 1:2 (Parkin and Muir, 1992; Ong et al, 1999;
Ramsay et al, 2000, 2002; Carroll et al, 2003). Most reports
have focused on the markedly increased risk of SCC, and
many have ignored BCC. The reported increased relative
risk for the development of BCC ranges from 10-fold in a
study of 769 renal transplant recipients in the Netherlands
(Hartevelt et al, 1990) to 1.4-fold in a study on 523 renal
transplant recipients in Canada (Gupta et al, 1989).
A robust model of ARD enhancement of non-melanoma
skin carcinogenesis—both the considerably more common
SCC as well as the less common BCC—would facilitate
greatly the study of the mechanism of the enhancement, the
screening of different drug regimens for their relative po-
tential to produce this side-effect, and the study of the in-
teractions of ARD with environmental and genetic factors.
The latter would be of particular interest, because not all
immunosuppressed patients develop NMSC, and in those
who do, the numbers of lesions vary considerably. The risk
is higher at those latitudes with more sunlight and is higher
within a region among those individuals who receive more
sun exposure (Bavinck et al, 1993). Most studies have found
the increased risk to correlate with time post-transplanta-
tion, male gender, ARD dosage, and older age at trans-
plantation (Jensen et al, 1999; Ong et al, 1999; Fortina et al,
2000; Naldi et al, 2000; Berg and Otley, 2002; Ramsay et al,
2002). Haired Ptch1þ / mice develop BCC-like tumors
after chronic exposure to ultraviolet (UV) light or after a sin-
gle treatment with ionizing radiation (IR) (Aszterbaum et al,
1999), and the BCC burden varies markedly according to
genetic background [(Pazzaglia et al, 2004); Epstein lab,
unpublished data]. These tumors develop slowly over 6 mo
and can be monitored microscopically. Therefore, this mod-
el permits the evaluation of different treatments and their
effects on BCC tumor formation (Hebert et al, 2001; Vogt
et al, 2004). We report here that long-term treatment with
cyclosporine A (CsA) and prednisolone significantly en-
hances IR-induced BCC in Ptc1þ / mice.
Results
Mice treated with ARD tolerated the injections well. Mice
that received ARD gained less weight than did those treated
with vehicle but there was no significant difference in the
survival between drug and solvent-injected mice (Fig 1). We
used the immune response of the mice to bovine serum
albumin (BSA) to assess the immunosuppressive effect of
the ARD treatment. Within 7 d after a single intraperitoneal
injection of 100 mg BSA in complete Freund’s adjuvant, ve-
hicle-treated mice uniformly developed antibodies against
the injected BSA; by contrast, no antibody response was
detected by ELISA or western blot assays in ARD-treated
animals (Fig 2). Similarly, delayed-type hypersensitivity
(DTH), expressed as the ratio between swelling of the
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BSA-injected ear and the saline-injected ear 48 h after
injection, was suppressed substantially in ARD-treated
mice—a reduction from 2.05- to 1.26-fold thickening.
At 32 wk of age, mice that had received injections with
CsA plus prednisolone had 2-fold more microscopic BCC
than did mice that had received injections with vehicle—
16.4 vs 8.4 for mean BCC number (17 vs 8 for median) per
standard biopsy (po0.0001). Mice treated with CsA plus
prednisolone also had 1.3-fold larger tumors than did ve-
hicle-treated mice—average BCC cross-sectional area
0.0036 mm2 (median 0.0036) as compared with 0.0029
mm2 (median¼ 0.0024) in controls (p¼0.016). Thus, the
BCC burden was increased 2.5-fold by ARD treatment—
0.063 in CsA vs 0.025 in control (0.06 vs 0.02 for median),
po0.001 (Fig 3, Table I). We detected no significant differ-
ence in the response to ARD between females and males.
Discussion
We were able to prosecute this study using CsA and pre-
dnisolone, a combination of immunosuppressive drugs
used widely in OTR, at doses that caused substantial sup-
pression of antibody formation and of cell-mediated immu-
nity but were well tolerated. Drug-treated mice developed
two times more and about 1.5-fold larger BCC tumors,
leading to a 2.5-fold increase in BCC tumor burden in mice
receiving CsA plus prednisolone over 4-1/2 mo. This model
seems particularly suitable for further studies in this field,
because, in contrast to animal models that use allogeneic
rejection of skin grafts or subcutaneously injected tumor cell
lines, Ptch1þ / mice endogenously develop BCC-like
tumors within several months and closely mimic the course
of disease in humans. In our model, enhancement of BCC
formation occurred in the absence of UV exposure, sug-
gesting that continued UV is not essential for drug-en-
hanced BCC formation and that the effects of the ARD in
this model were at a post-initiation stage of BCC develop-
ment. A small number of publications have reported that
ARD can enhance experimental mouse (mostly hairless)
squamous cell photocarcinogenesis but the reported en-
hancement is far less impressive than is the increased in-
cidence of SCC observed in human OTR (Koranda et al,
1975; Nathanson et al, 1976; Daynes et al, 1979; Reeve
et al, 1985; Kelly et al, 1987, 1989). These reported studies
used UV photocarcinogenesis and mostly used mutant
hairless mice, in which UV radiation primarily causes pap-
illomas and carcinomas of the squamous cell lineage. In
Figure 1
Effects of cyclosporineþprednisolone on mouse survival and growth. (A) Survival of mice. (B) weights of mice (left, males; right, females).
Dashed lines—mice receiving vehicles. Solid lines—mice receiving cyclosporine A (CsA) plus prednisolone.
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these models, the immunosuppressive effects of UV radi-
ation and ARD overlap, and the mice are genetically
immunoimpaired (San Jose et al, 2001). By contrast, we
have studied formation of BCC rather than of SCC and have
used Ptch1þ / mice of normal follicular structure and
without known immunoimpairment, and these mice develop
BCC-like tumors in response to chronic UV radiation or, as
in this study, to a single treatment with IR.
Inhibition of immunosurveillance is an assumed mecha-
nism for enhanced skin tumor formation in organ transplant
recipients. Evidence favoring this view includes the in-
creased incidence of NMSC in patients who have other
immunosuppressive disorders (Otley, 2002). But ARD affect
processes beyond immunosuppression. For example, CsA
alone has been reported to stimulate angiogenesis, to in-
hibit multidrug resistance pump activity, to inhibit DNA re-
pair, and to stimulate tumor cell activity directly (Hojo et al,
1999; Fortina et al, 2000; Gottsch and Akpek, 2000; Herman
et al, 2001; Guba et al, 2002; Sugie et al, 2002).
This model should be useful for investigation not only of
the mechanism of ARD enhancement of BCC formation,
admittedly with the proviso that mechanisms of enhance-
ment could differ depending on the environmental insult
(i.e., ionizing vs UV radiation), but also of genetic factors that
may help determine which OTR develops BCC. That such
genetic factors are important is suggested not only by the
marked differences in development of NMSC, both SCC
and BCC, in OTR within one population and between pop-
ulations [e.g. the incidence of NMSC is very low among OTR
of Asian or Hispanic ancestry [(Akiyama et al, 1998), R. Hi-
rose, UCSF, personal communication] but also by the
association of susceptibility to BCC with specific HLA
phenotypes in non-OTR (Bavinck et al, 2000)].
Materials and Methods
Mice The Ptch 1 knockout allele (Goodrich et al, 1997) was trans-
ferred onto the FVB/NJ background (Charles River Laboratories,
Wilmington, Massachusetts) and backcrossed  8. Mice were fed
Purina 5008 laboratory chow and water ad libitum, were housed in
a barrier facility in a windowless room in plastic cages with metal
lids at 50% humidity and ambient temperature of 701F–741F, and
were exposed daily to 12 h of white light from 34 W fluorescent
Figure 2
Primary antibody response against single injections of 100 lg bo-
vine serum albumin (BSA) in complete Freund’s adjuvant. ELISA
were performed on BSA-coated plates using sera from mice at a di-
lution of 1:200 (A). Western Blots: each of the six lanes is the assess-
ment of an individual mouse (B).
Figure3
Box plots of basal cell carcinoma (BCC) number, area, and burden
by treatment group. At the age of 8 mo, one 1 cm2 biopsy was taken
from the back of each mouse. The median number of BCC per mouse
(A), the median cross-sectional area of the tumors present in each
biopsy (B), and the median total tumor burden per biopsy (C) were
determined microscopically. Statistical analysis using the non-para-
metric Wilcoxon Rank Sum test showed a significant increase in tumor
number (po0.0001), area (p¼0.0016), and burden (po0.001) for mice
treated with cyclosporine A (CsA) plus prednisolone. Each rectangular
box indicates the interquartile range (25% and 75%), with the median
indicated by the horizontal line inside the box and the average indicated
by þ . The highest and lowest bars are the maximum and minimum
values.
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bulbs. At the age of 2 mo they were irradiated once with 5 Gy, using
a cesium-137 radiation device (Best Industries, Springfield, Virgin-
ia). All procedures were approved by the UCSF Institutional Animal
Care and Use Committee.
Drugs/treatment The clinically used stock solution containing 50
mg per mL CsA and 650 mg per mL Cremophor EL (SIGMA, St
Louis, Missouri) in 33.2% (vol/vol) absolute alcohol and water was
diluted in sterile saline and injected intraperitoneally (i.p.) at 50 mg
per g body weight in 100 mL. Prednisolone (SIGMA) was dissolved
in 0.85% sterile saline and administered subcutaneously (s.c.) in
the lower back at 10 mg per g body weight in 100 mL. Control mice
received 100 mL of a solvent stock solution of 650 mg Cremophor
EL (SIGMA) in 33.2% (vol/vol) absolute alcohol and sterile water
diluted in 0.85% sterile saline i.p. and 100 mL 0.85% sterile saline
s.c. Injections were given five times per week (Monday through
Friday) age 15–18 wk and three times per week (Monday, Wednes-
day, Friday) age 19–32 wk. Test and control solutions were pre-
pared freshly from stock solutions each morning before the
injections. Weight was measured every 2 wk.
Assessment of immune status The effects of CsA and predniso-
lone on primary antibody response and DTH were assessed in 10
study mice per group at the age of 7 mo (3 mo after the start of the
immunosuppressive therapy) using a protocol modified from Ber-
den et al (1986). BSA (SIGMA), 100 mg, in complete Freund’s ad-
juvant (SIGMA) was injected i.p. Blood was drawn from the tail vein
at day 10, and the primary immune response against BSA was
assayed by ELISA with confirmation of specificity by Western Blots.
Costar 96-well plates (Costar, Acton, Massachusetts) were coated
with 100 mg per mL BSA in 0.1 M NaHCO3, pH 9.6, 100 mL per well.
Blocking was performed with 0.1% gelatin in PBS and 0.1% Tween
20 (PBS-T), and 50 mL serum in PBS-T was added starting at a
dilution of 1/50. Plates were developed using a phosphatase-cou-
pled anti-mouse antibody (SIGMA, St Louis, Missouri) with p-nit-
rophenyl phosphate (SIGMA). Absorbance was read with a 96-well
plate reader (Fisher Scientific Thermo Labsystems Multiskan MCC/
340, Pittsburgh, Pennsylvania) at 405 nm. For the Western Blot,
samples of 10 mg BSA in SDS sample buffer were electrophoresed
on a 15% SDS gel and transferred onto a PVDP membrane using a
semi-dry system (E&K Scientific, Campbell, California). After trans-
fer, the membrane was cut in strips, which were then processed
separately in small gel chambers. Blots were blocked with 5% non-
fat dry milk in PBS, pH 7.4, and Tween 20 0.1% (PBS-T) for 1 h at
room temperature. Serum in blocking buffer was added at 1:50
dilution to each strip and was incubated for 1 h. Blots were de-
veloped using a peroxidase-coupled secondary anti-mouse anti-
body from SIGMA and the ECL Chemiluminescence Kit from
Amersham (Piscataway, New Jersey). All strips were exposed on
the same film to ensure that all control and test samples were
treated identically.
In order to assess BSA-specific DTH, the same mice were
challenged with 10 mL BSA, 2 mg per mL, in 0.85% sterile saline in
the right pinna. As control, 10 mL sterile saline was injected in the
left pinna. At 48 h after the injection, ear thickness was measured
using a calliper (Mitutoyo, Kanagawa, Japan). DTH reactivity was
expressed as the ratio between the thickness of the ear at the
antigen-injected site versus that at the saline-injected site.
Tumor sampling At the age of 8 mo, 1.0 cm2 of skin was taken
from the upper back of the mice and processed as described (As-
zterbaum et al, 1999). In brief, a 1  1 cm square of skin was
removed from the back, fixed in glutaraldehyde/formalin, and
incubated with X-gal and iron solution for detection of b-gala-
ctosidase enzyme activity to label the BCC (which have enhanced
hedgehog signalling and hence increased expression of this en-
zyme). The tissue was then ‘‘bread-loafed into three slices; one
section was prepared from each slice, and the slide was scored for
numbers and sizes of microscopic BCC with the observer blinded
as to the treatment of the mouse donor.’’
Statistics The Statistical Software package SAS (Cary, North
Carolina) was used to perform statistical analysis. Descriptive sta-
tistics including mean, median, and range were used to summarize
the study data (Table I). A box-plot was used for visual description
of the data (Fig 3). Because of the small sample size, a non-par-
ametric Wilcoxon Rank Sum test was used to determine the dif-
ferences among groups based on biological hypotheses.
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